Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andreasson, Burak Arslan, Mathias Droescher, Stefan Barghorn, Jeroen Vanbrabant, Charlotte Lambrechts, Maxime Van Loo, Erik Stoops, Shweta Iyengar, HaYeun Ji, Xiaomei Xu, Alex Forrest-Hay, Bingqing Zhang, Yuling Luo, Andreas Jeromin, Manu Vandijck, Nathalie Le Bastard, Hartmuth Kolb, Gallen Triana-Baltzer, Divya Bali, Shorena Janelidze, Shieh-Yueh Yang, Catherine Demos, Daniel Romero, George Sigal, Jacob Wohlstadter, Kishore Malyavantham, Meenakshi Khare, Alexander Jethwa, Laura Stoeckl, Johan Gobom, Przemysław R. Kac, Fernando Gonzalez-Ortiz, Laia Montoliu-Gaya, Oskar Hansson, Robert A. Rissman, Maria C. Carrillo, Leslie M. Shaw, Kaj Blennow, Jonathan M. Schott, Henrik Zetterberg
{"title":"阿尔茨海默病协会全球生物标志物标准化联盟（GBSC）血浆磷-tau循环研究","authors":"Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andreasson, Burak Arslan, Mathias Droescher, Stefan Barghorn, Jeroen Vanbrabant, Charlotte Lambrechts, Maxime Van Loo, Erik Stoops, Shweta Iyengar, HaYeun Ji, Xiaomei Xu, Alex Forrest-Hay, Bingqing Zhang, Yuling Luo, Andreas Jeromin, Manu Vandijck, Nathalie Le Bastard, Hartmuth Kolb, Gallen Triana-Baltzer, Divya Bali, Shorena Janelidze, Shieh-Yueh Yang, Catherine Demos, Daniel Romero, George Sigal, Jacob Wohlstadter, Kishore Malyavantham, Meenakshi Khare, Alexander Jethwa, Laura Stoeckl, Johan Gobom, Przemysław R. Kac, Fernando Gonzalez-Ortiz, Laia Montoliu-Gaya, Oskar Hansson, Robert A. Rissman, Maria C. Carrillo, Leslie M. Shaw, Kaj Blennow, Jonathan M. Schott, Henrik Zetterberg","doi":"10.1002/alz.14508","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD and show commutability in measuring patient samples and candidate certified reference materials (CRMs).</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Thirty-three different p-tau assays measured paired plasma and cerebrospinal fluid (CSF) from 40 participants (25 with “AD pathology” and 15 with “non-AD pathology” by CSF amyloid beta [Aβ]42/Aβ40 and p-tau181 criteria). Four CRMs were assessed.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Plasma p-tau217 demonstrated higher fold-changes between AD and non-AD than other p-tau epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, and Lilly MSD p-tau217 provided the highest fold-changes. Plasma p-tau217 showed the strongest correlations between plasma assays (rho = 0.81–0.97). The CRMs were not commutable across assays.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Plasma p-tau217 showed larger fold-changes and better accuracy for detecting AD pathology in symptomatic individuals, with greater cross-platform agreement than other p-tau variants. Further work is needed to develop suitable CRMs facilitating cross-assay standardization.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Paired plasma and cerebrospinal fluid (CSF) samples from twenty-five Alzheimer's disease (AD) and 15 non-AD patients were measured blind.</li>\n \n <li>Thirty-three plasma assays were compared, for phosphorylated tau-181 (p-tau181), 205, 212, 217 and 231.</li>\n \n <li>Plasma p-tau217 consistently had the highest fold-change and was best correlated between assays.</li>\n \n <li>Plasma-CSF correlations were weak to moderate.</li>\n \n <li>There was lack of commutability for four candidate reference materials.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14508","citationCount":"0","resultStr":"{\"title\":\"The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study\",\"authors\":\"Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andreasson, Burak Arslan, Mathias Droescher, Stefan Barghorn, Jeroen Vanbrabant, Charlotte Lambrechts, Maxime Van Loo, Erik Stoops, Shweta Iyengar, HaYeun Ji, Xiaomei Xu, Alex Forrest-Hay, Bingqing Zhang, Yuling Luo, Andreas Jeromin, Manu Vandijck, Nathalie Le Bastard, Hartmuth Kolb, Gallen Triana-Baltzer, Divya Bali, Shorena Janelidze, Shieh-Yueh Yang, Catherine Demos, Daniel Romero, George Sigal, Jacob Wohlstadter, Kishore Malyavantham, Meenakshi Khare, Alexander Jethwa, Laura Stoeckl, Johan Gobom, Przemysław R. Kac, Fernando Gonzalez-Ortiz, Laia Montoliu-Gaya, Oskar Hansson, Robert A. Rissman, Maria C. Carrillo, Leslie M. Shaw, Kaj Blennow, Jonathan M. Schott, Henrik Zetterberg\",\"doi\":\"10.1002/alz.14508\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD and show commutability in measuring patient samples and candidate certified reference materials (CRMs).</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>Thirty-three different p-tau assays measured paired plasma and cerebrospinal fluid (CSF) from 40 participants (25 with “AD pathology” and 15 with “non-AD pathology” by CSF amyloid beta [Aβ]42/Aβ40 and p-tau181 criteria). Four CRMs were assessed.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Plasma p-tau217 demonstrated higher fold-changes between AD and non-AD than other p-tau epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, and Lilly MSD p-tau217 provided the highest fold-changes. Plasma p-tau217 showed the strongest correlations between plasma assays (rho = 0.81–0.97). The CRMs were not commutable across assays.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Plasma p-tau217 showed larger fold-changes and better accuracy for detecting AD pathology in symptomatic individuals, with greater cross-platform agreement than other p-tau variants. Further work is needed to develop suitable CRMs facilitating cross-assay standardization.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Paired plasma and cerebrospinal fluid (CSF) samples from twenty-five Alzheimer's disease (AD) and 15 non-AD patients were measured blind.</li>\\n \\n <li>Thirty-three plasma assays were compared, for phosphorylated tau-181 (p-tau181), 205, 212, 217 and 231.</li>\\n \\n <li>Plasma p-tau217 consistently had the highest fold-change and was best correlated between assays.</li>\\n \\n <li>Plasma-CSF correlations were weak to moderate.</li>\\n \\n <li>There was lack of commutability for four candidate reference materials.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 2\",\"pages\":\"\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2025-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14508\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14508\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14508","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study
INTRODUCTION
The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD and show commutability in measuring patient samples and candidate certified reference materials (CRMs).
METHODS
Thirty-three different p-tau assays measured paired plasma and cerebrospinal fluid (CSF) from 40 participants (25 with “AD pathology” and 15 with “non-AD pathology” by CSF amyloid beta [Aβ]42/Aβ40 and p-tau181 criteria). Four CRMs were assessed.
RESULTS
Plasma p-tau217 demonstrated higher fold-changes between AD and non-AD than other p-tau epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, and Lilly MSD p-tau217 provided the highest fold-changes. Plasma p-tau217 showed the strongest correlations between plasma assays (rho = 0.81–0.97). The CRMs were not commutable across assays.
DISCUSSION
Plasma p-tau217 showed larger fold-changes and better accuracy for detecting AD pathology in symptomatic individuals, with greater cross-platform agreement than other p-tau variants. Further work is needed to develop suitable CRMs facilitating cross-assay standardization.
Highlights
Paired plasma and cerebrospinal fluid (CSF) samples from twenty-five Alzheimer's disease (AD) and 15 non-AD patients were measured blind.
Thirty-three plasma assays were compared, for phosphorylated tau-181 (p-tau181), 205, 212, 217 and 231.
Plasma p-tau217 consistently had the highest fold-change and was best correlated between assays.
Plasma-CSF correlations were weak to moderate.
There was lack of commutability for four candidate reference materials.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
